Clinical Trial Update: Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056 [Phase 1]

View source ↗

Summary

A Phase 1 cross-over study assessed retinal function after a single dose of AZD9056 in rheumatoid arthritis patients; the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• AZD9056

Snippet

Sponsor: AstraZeneca | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED